1 / 48

Role of CRRT in Sepsis

Role of CRRT in Sepsis. Dr Apoorva Jain Agra. SEPSIS: BACKGROUND. Severe Sepsis and Septic Shock are the primary causes of Multiple Organ Dysfunction Syndrome (MODS) [of which Acute Renal Failure-is part of] One of the most common cause of mortality in the ICU setting.

xue
Download Presentation

Role of CRRT in Sepsis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Role of CRRT in Sepsis Dr Apoorva Jain Agra

  2. SEPSIS: BACKGROUND • Severe Sepsis and Septic Shock are the primary causes of Multiple Organ Dysfunction Syndrome (MODS) [of which Acute Renal Failure-is part of] • One of the most common cause of mortality in the ICU setting

  3. SEPSIS: BACKGROUND • Variety of Water soluble mediators with Pro & Anti- Inflammatory Activities play a strategic role in Septic Syndrome including (but not limited to): TNF, IL-6,IL-8 and IL-10, Kinins, Thrombins, heat shock proteins

  4. SEPSIS: BACKGROUND • Stimulus –Receptor coupling sets off the signal transduction cascade resulting in exacerbated generation of; Platelet activating factor, cytokines, leukotrienes, Arachidonic acid derivatives etc.) and activation of the complement cascade and coagulation pathways.

  5. SEPSIS: Pathophysiology • Dysfunctional homeostatic balance results in increased biological activity of sepsis associated mediators and loss of control over these by specific inhibitors-cell hypo-responsiveness • This excessive anti-inflammatory counterpart to SIRS has been coined “CARS- Compensated Anti-inflammatory Response Syndrome” • Bone et al. Chest 112:235-43, 1997

  6. Goals of Treatment are hemodynamic and relate to outcome • Early Goal-Directed Therapy in the treatment of Severe Sepsis and Septic Shock. Rivers E, N Engl J Med 2001;345:1368-1377. • RCT 130 adults randomized to aggressive care In First few hours • Results: In Hospital Mortality 30.5% vs 46.5% in Controls • Early goal directed therapy improves shock outcome(Han Y. 2000 Pediat Res 47:108a. Ceneviva G. Pediatrics 1998;102:e19.)

  7. OUTLINE • 1 CRRT for Sepsis - associated AKI • 2. CRRT as Immunomodulatory therapy

  8. CRRT for Sepsis-associated AKI

  9. CRRT for Sepsis-associated AKI • Role & Indications • Dosing • Alternative therapies

  10. CRRT for Sepsis-associated AKI • Dialysis allows: – Correction of acid-base status – Correction of electrolyte abnormalities – Clearance of toxins – Control of fluid balance

  11. CRRT for Sepsis-associated AKI • Advantages of using CRRT • Suitable for use in hemodynamically unstable patients • Precise, adaptable, volume control • Very effective control of uremia, PO4, K • Rapid control of metabolic acidosis • Improved nutritional support (full protein diet) • Available 24 hours a day • May have an effect as an adjuvant therapy in sepsis

  12. CRRT for Sepsis-associated AKI • Disadvantages of using CRRT • Expense – more than IHD, due to fluids • Continuous anticoagulation may be required • Risk of line disconnection • Hypothermia • Severe depletion of electrolytes (K and PO4), nutrients

  13. CRRT for Sepsis-associated AKI • Dosing of dialysis in AKI • 425 patients randomized • Post-dilution CVVH mode • only 12% had sepsis Ronco et al, Lancet 2000; 355: 26

  14. CRRT for Sepsis-associated AKI • Modes of CRRT

  15. CRRT for Sepsis-associated AKI • Modes of CRRT

  16. CRRT for Sepsis-associated AKI • Modes of CRRT

  17. CRRT for Sepsis-associated AKI • Dosing of dialysis in AKI • 206 patients randomized • 60% sepsis • CVVH versus CVVH + added D Saudan et al, Kidney Int 2006; 70:1312

  18. CRRT for Sepsis-associated AKI • Negative dosing studies • 200 patients • CVVHDF 20 v 35 ml/kg/hr • No difference Tolwani et al J Am Soc Nephrol 2008; 19:1233 • 1124 patients, multicentred (NIH ATN study) • Intensified (35ml/kg, 6x/wk IHD) versus • Standard (20ml/kg, 3x/wk IHD) • No difference Palevsky et al N Engl J Med 2008; 359:7.

  19. CRRT for Sepsis-associated AKI • Reasons for differences • Delayed initiation of RRT in Tolwani and ATN studies: 6 to 8 days • No clear separation of dose delivered when combining CRRT and IHD dosing (ATN study) • Majority (65%) enrolled after initial dialysis • Dosing was not actually achieved in the ATN study

  20. CRRT for Sepsis-associated AKI • RENAL study • 1508 patients, approx 50% sepsis • 48-54 hr in ICU before randomisation • Prescribed dose achieved: 84 – 88% • CVVHDF, postdilution (1:1 dialysate:filtration) • Low intensity: 25 ml/kg/hr • High intensity: 40 ml/kg/hr • No difference in mortality N Engl J Med Oct 22nd, 2009.

  21. CRRT for Sepsis-associated AKI • Alternative therapies • IHD • mortality higher in many CRRT studies • 5 RCT’s: no difference in mortality • 7 meta-analyses: no differences

  22. CRRT for Sepsis-associated AKI • Alternative therapies Kellum et al. Intensive Care Med 2002; 28:29

  23. CRRT for Sepsis-associated AKI • Alternative therapies Bagshaw et al, Crit Care Med 2008; 36:610

  24. CRRT for Sepsis-associated AKI • Alternative therapies • IHD • mortality higher in many CRRT studies • 5 RCT’s: no difference in mortality • 7 meta-analyses: no differences • SLED: sustained low efficiency dialysis • safe, effective, cheaper than CRRT • limited comparative data Berbece & Richardson, Kidney Int 2006; 70:963

  25. Epidemiology of AKI • BEST Kidney study: • 23 countries, over 30,000 patients, 2001 • 1738 developed acute renal failure • Dialysis • CRRT 80% --- • IHD 17% • SLED/PD 3% • Hospital mortality 60% CVVH 53% CVVHD 13% CVVHDF 34% Uchino et al, JAMA 2005; 294:813 Uchino et al, Intensive Care Med, 2007 33:1563

  26. CRRT as Immunomodulatory therapy

  27. CRRT as Immunomodulatory therapy • Background & rationale • Studies supporting this hypothesis • Clinical studies • Variations on standard CRRT

  28. CRRT as Immunomodulatory therapy • Rationale – Removal of “Bad Humours”

  29. CRRT as Immunomodulatory therapy • Rationale – Removal of “Bad Humours”

  30. CRRT as Immunomodulatory therapy

  31. CRRT as Immunomodulatory therapy Ronco et al. Artiforgans 2003; 27:792

  32. CRRT as Immunomodulatory therapy Ronco et al. Artiforgans 2003; 27:792

  33. CRRT as Immunomodulatory therapy • Mechanism of cytokine removal • Convective • High flux membranes cut-off 30 – 40 kD • Should remove many cytokines (17 – 30 kD) • Is removal rate significant given high production? • Adsorption • Filter dependent: higher with polyacrylonitrile (AN69) than with polysulfone membranes

  34. CRRT as Immunomodulatory therapy • Convective therapy can: • Remove cytokines • In some, but not all studies • Adsorption important • Frequent filter changes • Plasma levels unchanged • Improve hemodynamics • In animal studies • In open clinical studies Heering et al Intensive Care Med. 1997;23:288

  35. CRRT as Immunomodulatory therapy • 15 pts, sepsis, AKI • first 24 hr hemofiltration • AN69 filter De Vriese et al. J Am Soc Nephrol 1999;10:846-853

  36. CRRT as Immunomodulatory therapy Morgera et al. Crit Care Med 2006; 34:2099

  37. CRRT as Immunomodulatory therapy Morgera et al. Crit Care Med 2006; 34:2099

  38. CRRT as Immunomodulatory therapy • Outcome studies

  39. CRRT as Immunomodulatory therapy • Ronco study Ronco et al, Lancet 2000; 355: 26

  40. CRRT as Immunomodulatory therapy • RENAL study

  41. CRRT as Immunomodulatory therapy • CRRT without AKI • Sepsis, no renal failure • CVVH, 2L/hr, AN69 filter • No significant reduction in cytokines • No clinical benefit Cole et al, Crit Care Med 2002; 30:100

  42. CRRT as Immunomodulatory therapy • Outcome studies • 80 patients, early CVVH 25ml/kg/hr or control • High flux polysulfone filter Payen et al Crit Care Med 2009; 37:803

  43. CRRT as Immunomodulatory therapy • Outcome studies • 80 patients, early CVVH 25ml/kg/hr or control • High flux polysulfone filter • No benefit, deleterious? Payen et al Crit Care Med 2009; 37:803

  44. CRRT as Immunomodulatory therapy • Outcome studies • 80 patients, early CVVH 25ml/kg/hr or control • High flux polysulfone filter • No benefit, deleterious? Payen et al Crit Care Med 2009; 37:803

  45. CRRT as Immunomodulatory therapy • Outcome studies • 80 patients, early CVVH 25ml/kg/hr or control • High flux polysulfone filter • No benefit, deleterious? • Can’t expect a mortality benefit with the wrong intervention in the wrong dose Payen et al Crit Care Med 2009; 37:803

  46. Variations on standard CRRT • High volume hemofiltration • High cutoffhemofiltration • Plasmafiltration • Cascade filtration • Coupled plasma filtration adsorption

  47. Thank You!

More Related